Passage of the capsule endoscope to the colon occurs in only approximately 3/4 of patients.
Dr Selby from Sydney, Australia undertook a study in order to assess factors that might influence the completeness of small-bowel transit, including orally administered metoclopramide.
The researchers prospectively recorded clinical and procedural parameters for 150 patients undergoing capsule endoscopy.
The investigators did not administer metoclopramide to the first 83 patients (Group 1) but did give it orally (10 mg) to the subsequent 67 (Group 2).
The researchers noted that small-bowel transit was complete in 63 patients in Group 1 (76%).
|In Group 2 (metoclopramide), the capsule reached the colon in 97% patients|
The team found that gastric transit time was significantly longer when the capsule did not reach the colon than when it did (115 minutes vs. 27 minutes).
In addition, they noted that small-bowel transit time was longer.
The likelihood of complete small-bowel passage was not predicted by any clinical or procedural factor.
The researchers found that in Group 2 (metoclopramide), the capsule reached the colon in 97% patients.
This improvement was associated with a significant reduction in gastric transit time (48 minutes vs. 31 minutes).
Dr Selby concluded, "Metoclopramide increases the likelihood of a complete small-bowel examination in patients undergoing capsule endoscopy."